C5AR1 and anti-neutrophil cytoplasmic antibody-associated vasculitis: In the context of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), the C5aR inhibitor avacopan, whether administered alone or in combination with low-dose corticosteroids, demonstrated non-inferiority but not superiority to standard high-dose corticosteroid treatment [293].